Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Histogen Inc. HSTO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Histogen Inc. (HSTO) is a Biotechnology company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $4M, +57.6%/yr average growth. Net income is $11M (loss), growing at -5.2%/yr. Net profit margin is -281.8% (negative). Gross margin is 100% (+20.6 pp trend).

Balance sheet: total debt is $5M against $14M equity (Debt-to-Equity (D/E) ratio 0.32, conservative). Current ratio is 10.9 (strong liquidity). Debt-to-assets is 24.3%. Total assets: $19M.

Analyst outlook: 2 / 2 analysts rate HSTO as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

HSTO SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HSTO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
HSTO: +57.6%/yr revenue is, -5.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet HSTO: Debt-to-Equity (D/E) ratio 0.32 (conservative), Current ratio is 10.9 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
HSTO: Gross margin is 100% (+20.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate HSTO as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HSTO: Net profit margin is -281.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
Market Cap$85.44K
Beta (1Y)1.12
Share Statistics
EPS (TTM)-3.46
Shares Outstanding$3.21M
IPO Date2013-07-25
Employees7
CEOSusan A. Knudson
Financial Highlights & Ratios
Revenue (TTM)$3.77M
Gross Profit$3.77M
EBITDA$-10.5M
Net Income$-10.62M
Operating Income$-10.64M
Total Cash$12.51M
Total Debt$4.63M
Net Debt$-7.48M
Total Assets$19.07M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.02
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS43358Y2028

Price Chart

Track all markets on TradingView
HSTO
Histogen Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology

People Also View

DRUG
DRUG
Bright Minds Biosciences Inc.
$89.62
+0.54%
 PALI
PALI
Palisade Bio, Inc.
$2.34
+13.59%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$14.34
+7.42%
 YS
YS
YS Biopharma Co., Ltd.
$1.02
+9.68%
 ENTX
ENTX
Entera Bio Ltd.
$1.18
+4.42%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 CING
CING
Cingulate Inc.
$5.20
-2.80%
 SNTI
SNTI
Senti Biosciences, Inc.
$0.94
+0.73%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message